LYRA

Investor Moves

Name	Value	Action	Change	Price	Current Price
Ken GriffinCitadel Advisors $-128.4K ExitQ4 2025 $128k -- $0.52

Insider Trades

Name	Value	Action	Price	Current Price
Cavalier JasonChief Financial Officer $2.6k769 shares SellJan 6, 2026 $3.36 $0.52
Palasis MariaDirector, Officer: President & CEO $5.7k1.7k shares SellJan 6, 2026 $3.36 $0.52
Perceptive Advisors LLC10 Percent Owner $3.6k883 shares SellNov 12, 2025 $4.06 $0.52
Perceptive Advisors LLC10 Percent Owner $2.3k537 shares SellNov 11, 2025 $4.31 $0.52
Perceptive Advisors LLC10 Percent Owner $112k28.6k shares SellNov 13, 2025 $3.90 $0.52
Perceptive Advisors LLC10 Percent Owner $32k7.9k shares SellNov 12, 2025 $4.06 $0.52

News

globenewswire.comLyra Therapeutics, Inc. Announces Intention to Voluntarily File Form 25 for Delisting from Nasdaq and Subsequent Deregistration with the SECglobenewswire.comApr 17

Trade LYRA

About Lyra Therapeutics, Inc.

Lyra Therapeutics, Inc. operates as a clinical-stage biotechnology company, primarily focused on the creation and commercialization of anti-inflammatory treatments for individuals suffering from chronic rhinosinusitis (CRS). The company's unique technological approach allows for the direct delivery of therapeutic agents to the targeted tissue, ensuring prolonged efficacy from a singular dose. Its pipeline features several promising candidates, including LYR-210, an anti-inflammatory implantable drug matrix currently in Phase III clinical trials for CRS. Additionally, LYR-220 is under development for CRS patients who have not responded to previous medical treatments and still require intervention for their symptoms. Lyra has forged a partnership with LianBio Inflammatory Limited to facilitate the development and market entry of LYR-210 throughout specific Asian regions, encompassing mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. Established in 2005, the company was initially known as 480 Biomedical, Inc. before adopting the name Lyra Therapeutics, Inc. in July 2018. Its corporate headquarters are located in Watertown, Massachusetts.

CEO: Carmichael S. Roberts Jr.
IPO Date: May 1, 2020

Market Data

Open: $0.4633
High: $0.48
Low: $0.44
Volume: 77.9K
Avg Volume: 106.4K
52W High: $37.50
52W Low: $0.4401

Valuation

Market Cap: $781.1K
Enterprise Value: $15.1M
Dividend Yield: 0.00%

Financials

Free Cash Flow: -$29M
Revenue: $398K
Net Income: -$28.9M
Cash: $15.9M
Debt: $30.3M

Events

EarningsMay 12

EPS est. -1.36